Previous 10 | Next 10 |
EVANSTON, Ill., June 18, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment in its ongoing Phase 2 explorat...
EVANSTON, Ill., June 16, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that company management will be presenting at the follo...
Introduction The Weekly Breakout Forecast continues my doctoral research analysis on MDA breakout selections over more than five years. This subset of the different portfolios I regularly analyze has now reached 158 weeks of public selections as part of this ongoing live forward-testing re...
Aptinyx Inc. (APTX) Q1 2020 Earnings Conference Call May 14, 2020, 05:00 PM ET Company Participants Nick Smith - Senior Director, Corporate Development & IR Norbert Riedel - President & CEO Ashish Khanna - CFO & Chief Business Officer Andy Kidd - COO Catherine Kin...
Aptinyx (NASDAQ: APTX ): Q1 GAAP EPS of -$0.34 misses by $0.02 . More news on: Aptinyx Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Over 90% of target enrollment achieved to date in Phase 2 exploratory study of NYX-783 in PTSD; data readout expected in late 2020 Cash balance of $121 million expected to support planned operations into 2022 Conference call today at 5:00 p.m. EDT EVANSTON, Ill., May 14, 2020 (...
EVANSTON, Ill., April 30, 2020 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live ...
Aptinyx Inc. (APTX) Q4 2019 Results Earnings Conference Call March 30, 2020, 05:00 PM ET Company Participants Nick Smith - Senior Director, Corporate Development and Investor Relations Norbert Riedel - President and Chief Executive Officer Ashish Khanna - Chief Financial Officer ...
Aptinyx (NASDAQ: APTX ): Q4 GAAP EPS of -$0.41 beats by $0.15 . More news on: Aptinyx Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Initiated four Phase 2 clinical studies based on compelling prior data Actions taken on ongoing clinical studies due to COVID-19 pandemic Strong cash position following recently completed common stock offering provides runway into 2022 Conference call today at 5:00 p.m. EDT ...
News, Short Squeeze, Breakout and More Instantly...
Signature Bank (SBNY) is expected to report for Q3 2023 BHP Group Ltd. (BHP) is expected to report for Q1 2024 Sorrento Therapeutics Inc. (SRNEQ) is expected to report $-0.15 for Q3 2023 Baran Group Ltd. (BRANF) is expected to report for quarter end 2023-09-30 World Copper (WCUFF)...
GLG Life Tech Corporation (GLGLF) is expected to report for Q1 2024 Accenture plc Class A (Ireland) (ACN) is expected to report $3.14 for Q1 2024 Greenlane Holdings Inc. (GNLN) is expected to report $-2.7 for Q3 2023 iMedia Brands Inc. (IMBIQ) is expected to report for quarter end 202...
Axcella Health Inc. (AXLA) is expected to report for Q3 2023 Telekom Malaysia Bhd (MYTEF) is expected to report for quarter end 2023-09-30 Atento S.A. (ATTOF) is expected to report for Q3 2023 Scryb Inc Com (SCYRF) is expected to report for Q4 2023 BHP Group Ltd. (BHP) is expected...